Neoadjuvant nivolumab plus chemotherapy improves overall survival in resectable NSCLC Summary Neoadjuvant nivolumab combined with chemotherapy significantly improves overall survival (OS) in patients with resectable non-small cell lung cancer (NSCLC) compared to chemotherapy alone. This Read More